EBS: Emergent Corp Price Target Chart

The asset value of Emergent BioSolutions (EBS) reflected in the pakistan chart demonstrates the dynamics of a strategic Washington ally in biodefense with an impeccable image. Emergent BioSolutions generates revenue from Narcan spray sales and government contracts for anthrax vaccination, while the consensus forecast stands at 9.96. Despite exclusive contracts, the firm's position is weakened by costs associated with remediating manufacturing deficiencies required by the FDA.

Emergent Bio (EBS): Price Target Chart from 07/04/2022 to 11/11/2026

Analytical breakdowns for Emergent Corp (EBS)

- current quotes and average value forecast:

Market Price emergentbiosolutions.com|EBS - Analyst Consensus Forecast

- market capitalization information:

Market Value Emergent Corp|EBS - Total Company Value

- issuer book value statistics:

Net Assets per Share Emergent BioSolutions|EBS - Company Book Value|Market Capitalization to Net Assets emergentbiosolutions.com|EBS - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

EBS - Net Income|Expected Net Income Emergent BioSolutions|EBS - Price to Earnings Ratio|Future Price to Earnings Emergent BioSolutions Inc|EBS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Emergent Corp|EBS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Emergent BioSolutions|EBS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth emergentbiosolutions.com|EBS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Emergent BioSolutions

Fundamental company analysis:emergentbiosolutions.com, EBS

For an Emergent BioSolutions (EBS) investor, this indicator combines market capitalization expectations with the efficiency of the company's external logistics and IT outsourcing. By analyzing the weighted average price target on GURU.Markets, one can assess the ratio of current multiples to projected earnings, where the stability of the curve confirms the resilience of fundamental business processes and the predictability of the issuer's cash flows.

Competitors of Emergent BioSolutions